Topics

Clinical Trials About "Completes Expansion Specialty Drug Product Capabilities" RSS

21:00 EST 23rd January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Completes Expansion Specialty Drug Product Capabilities" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Completes Expansion Specialty Drug Product Capabilities" on BioPortfolio

We have published hundreds of Completes Expansion Specialty Drug Product Capabilities news stories on BioPortfolio along with dozens of Completes Expansion Specialty Drug Product Capabilities Clinical Trials and PubMed Articles about Completes Expansion Specialty Drug Product Capabilities for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Completes Expansion Specialty Drug Product Capabilities Companies in our database. You can also find out about relevant Completes Expansion Specialty Drug Product Capabilities Drugs and Medications on this site too.

Showing "Completes Expansion Specialty Drug Product Capabilities" Clinical Trials 1–25 of 7,200+

Relevant

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

The purpose of this study is to determine the safety of AZX100 Drug Product and to determine whether it is effective in preventing or reducing re-growth of surgically removed keloid scars.


A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

The purpose of this study is to determine the safety of AZX100 Drug Product and to determine whether it is effective in preventing or reducing re-growth of surgically removed keloid scars.

A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Produc

Approximately 140 male and female healthy subjects will be randomized (1:1 ratio) to receive a 120 mg single dose of denosumab either as a 1.7 mL single injection of 70 mg/mL denosumab CP4 (Treatment A) or as a 1.7 mL single injection of 70 mg/mL denosumab CP2 (Treatment B). Subjects will be admitted to the research facility on day -1 and remain in the research facility through day 2. The subjects will return to the research facility on an outpatient basis. The PK, PD, and safe...


A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who Have a β0/β0 Genotype

This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 15 subjects ≥12 and ≤50 years of age with transfusion-dependent β-thalassemia (TDT), who have a β0 mutation at both alleles of the β-globin (HBB) gene (i.e. β0/β0). The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.

Specialty Mental Health Probation in North Carolina

Specialty mental health probation for offenders with severe mental illness has been widely disseminated; however, randomized studies are needed to determine its effectiveness. The purpose of the study is to test the feasibility and efficacy of specialty mental health probation (SMHP) for probationers with mental illness in North Carolina. 320 adult probationers with mental illness in will be randomly assigned to specialty mental health probation (experimental condition) or usua...

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

In response to the growing need for training on interventions to address first episode psychosis, the Center for Social Innovation (C4) has partnered with experts in Coordinated Specialty Care (CSC) to develop and test CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care. The product builds on the findings of the Recovery After an Initial Schizophrenia Episode (RAISE) studies, funded by the National Institute of Mental Health (NIMH). ...

To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

The purpose of this study is to compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of actinic keratosis.

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

In response to the growing need for training on interventions to address first episode psychosis, the Center for Social Innovation (C4) has partnered with experts in Coordinated Specialty Care (CSC) to develop and test CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care. The product builds on the findings of the Recovery After an Initial Schizophrenia Episode (RAISE) studies, funded by the National Institute of Mental Health (NIMH). ...

Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging

This Protocol is intended to facilitate development and testing of new cardiovascular MRI software capabilities by UC Davis Research Faculty, as well as to facilitate the evaluation of new software capabilities provided by GE and Siemens.

Implementation of a Targeted Intervention to Decrease Rates of Non-adherence in a Specialty Population

Patients deemed non-adherent to their specialty medications will be randomized to receive a pharmacist-driven intervention or the standard of care. Medication adherence will be measured at 4-months and 8-months post-randomization to determine if the intervention improved specialty medication adherence.

A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product

This protocol intends to detail investigations necessary to evaluate the ocular safety of subjects enrolled in study A4321001 and who have received formulated Drug Product (Lot 8716-098).

A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects

This is a non-randomized, open label, multi-site, single-dose, Phase 1/2 study in up to 18 subjects (including at least 3 adolescents between 12 and 17 years of age, inclusive) with beta-thalassemia major. The study will evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin® BB305 Drug Product [autologous CD34+ hematopoietic stem cells transduced with LentiGlobin® BB305 Lentiviral Vector encoding the human β-A(T87Q)-g...

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

The main purpose of study is to compatibility the pharmacokinetic (PK) of Process D relative to Process C.

Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flap

DESIGN: Non-inferiority Randomized Controlled Trial (RCT). Patients undergoing free flap reconstructive surgery at UCDMC will be assigned randomly into no intervention group (immediate post operative care in an Intensive Care Unit) or intervention group (immediate post operative care in a non-ICU specialty ward). HYPOTHESIS: There is no significant difference in the length of stay (LOS) or complication rate between head and neck free flaps patients managed immediately post-ope...

The Pilot Project Development Of MEdical Rehabilitation System in Russian Federation

The Programme is focused on adult patients of any gender and age more than 18 y.o., with the next conditions: 1. Acute cerebrovascular events (ACE, ischemic stroke or intracerebral hemorrhage - specialty neurology) 2. Acute myocardial infarction (AMI, specialty cardiology) 3. Patients after total hip replacement (THR, specialty orthopaedia) The program is performed in the in-patient and out-patient rehabilitation departments in 13 regions of ...

Bioavailability of Dienogest 2.0 mg With Regards to Reference Product

This Pivotal study will investigate the bioavailability in women of 1 tablet formulations containing Dienogest 2.0 mg. The Pivotal study will be performed at a single site with 30 subjects. Participants will take 1 tablet of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.

Comparing the Effectiveness of Lung Expansion Therapy in Adult Human Subjects

The purpose of this study is to better understand how air is spread throughout your lungs after your abdominal surgery by comparing two lung inflation treatments: 1. Incentive Spirometry (I.S.) lung expansion therapy 2. EzPAP® lung expansion therapy. Lung expansion therapy is routinely used after your type of surgery. Taking deep breaths after surgery helps your lungs to stay inflated. At the University of Virginia, it is at the physician's discretion as to which ...

CSD190301: A Study to Assess Elements of Abuse Liability for Two Dissolvable Nicotine Lozenge Tobacco Products

This is a two-arm, single use, single-center, randomized, 10-sequence per arm, open-label, crossover pharmacokinetic/pharmacodynamic (PK/PD) study, designed to evaluate elements of abuse liability (AL) including subjective effects, plasma nicotine uptake, and physiological measures during and following ad libitum use of the study investigational products (IPs) by generally healthy subjects.

Randomized, Multi-Dose, Placebo-Controlled OA Knee Pain Relief Study of 0.25% 920-CGS-200

This is a study of a OTC TFM compliant, capsaicin-based (0.25%) topical analgesic for management of osteoarthritis (OA) knee pain (OAKP). Subjects meeting the inclusion criteria and not meeting the exclusion criteria will be randomized into one of four groups: once daily treatment with active product, once daily treatment with product vehicle (no capsaicin), twice daily treatment with active product, and twice daily treatment with product vehicle (no capsaicin), all for 7 conse...

A Study to Compare US Marketed Pancrelipase Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis.

This is a study to demonstrate that pancrelipase Delayed Release (DR) capsules manufactured with a Modernized Process (MP) is non-inferior to currently marketed pancrelipase DR capsules in participants with EPI due to Cystic Fibrosis (CF), as measured by Coefficient of Fat Absorption (CFA). Safety will also be evaluated.

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

The purpose of the study is determine if the local release characteristics and systemic exposure to tenofovir (TFV) 1% gel and a given commonly used vaginal product are impacted by concomitant use

In Vivo Sun Protection Factor Determination

The study aims to determine the Sun Protection Factor (SPF) of 8 cosmetic products in vivo on the back of human participants, according to the International Standard Sun Protection Test method by using a sun simulator.

Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room

This study will combine coronary stenting with minimally invasive robotic coronary bypass surgery, accomplished with the use of the da Vinci robot, to restore blood flow to occluded coronary arteries. Two previously approved and commonly performed procedures used to treat coronary artery disease(coronary stenting and robotic bypass surgery) are being combined into a hybrid surgery in a specialty built operating room. Patients with low risk coronary lesions will undergo cardia...

Pain and Discomfort During Maxillary Expansion: mRCT

The aim of the present study is to investigate and analyze the perception of pain and function impairment during the first week of activation with two different palatal expansion screw to identify an effective pain prevention protocol.


More From BioPortfolio on "Completes Expansion Specialty Drug Product Capabilities"

Quick Search